Home>Topics>Companies>Forest Laboratories

Forest Laboratories FRX

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. New Morningstar Analyst Report for Actavis PLC

      Stock Reports

      Wed, 12 Mar 2014

      value estimate for Actavis to $200 per share from $168 after incorporating potential synergies from the announced Forest Laboratories acquisition. As long as management can achieve its $1 billion cost synergy target, the deal should push annual free cash

    2. M&A: A New Rx for Specialty Pharma

      Headlines

      Mon, 10 Mar 2014

      well-aligned with shareholders. At Forest Laboratories , for example, the new CEO put ..... Ireland. Likewise, Actavis and Forest Laboratories were up 17% and 39%, respectively ..... mid-February it would acquire Forest Laboratories . The secular trends favoring

    3. New Morningstar Analyst Report for Forest Laboratories , Inc.

      Stock Reports

      Wed, 8 Jan 2014

      been put to to work for shareholders returning hundreds of millions of dollars per year in additional earnings. Forest Laboratories is a pharmaceutical company focused on in-licensing drugs for development. The company's portfolio includes

    4. Forest Labs' longtime CEO Solomon to step down at year-end

      Headlines

      Thu, 23 May 2013

      May 23 (Reuters) - Forest Laboratories Inc said on Thursday that Howard Solomon, who has led the biotech firm since 1977, will retire as chief executive officer at the end of this year and the...

    5. 10 High-Conviction Purchases by Our Ultimate Stock Pickers

      Headlines

      Tue, 21 May 2013

      when expanded out to 25 names) included Air Products & Chemicals APD, American Express AXP, Best Buy BBY, Forest Laboratories FRX, Freeport-McMoRan Copper & Gold FCX, Kohl's KSS, Mondelez International MDLZ, Morgan Stanley MS, Oracle

    6. AstraZeneca Posts Solid Fourth Quarter, but Offers Weak 2013 Guidance and Removes 2014 Guidance

      Commentary

      Thu, 31 Jan 2013

      weak pipeline increases the likelihood that AstraZeneca will look for a major acquisition in 2013, and we think Forest Laboratories FRX is a likely target, as its valuation looks attractive and the firm holds several recently approved drugs

    7. Forest Labs profit tumbles as generics hammer sales

      Headlines

      Tue, 16 Oct 2012

      (Reuters) - Forest Laboratories Inc , hit hard by generic rivals to its antidepressant Lexapro, posted a sharp drop in quarterly profit on Tuesday and forecast full-year results below analysts'...

    8. Icahn may win one board seat at Forest Labs-sources

      Headlines

      Wed, 15 Aug 2012

      Aug 15 (Reuters) - Billionaire investor Carl Icahn, who has nominated four candidates to the board of Forest Laboratories Inc, may win one board seat, according to a preliminary tally of shareholder...

    « Prev12345Next »
    Content Partners